Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35
- 491 Downloads
Type 2 diabetes mellitus (T2DM) is a common disease with numerous complications. Bariatric surgery is an efficient procedure for controlling T2DM in morbidly obese patients. In T2DM, the incretin effect is either greatly impaired or absent. This study aimed to evaluate the preliminary results from interposing a segment of ileum into the proximal jejunum associated with a sleeve or diverted sleeve gastrectomy to control T2DM in patients with a body mass index (BMI) less than 35 kg/m2.
For this study, 39 patients (16 women and 23 men) underwent two laparoscopic procedures comprising different combinations of ileal interposition into the proximal jejunum via a sleeve or diverted sleeve gastrectomy. The mean age of these patients was 50.3 years (range, 36–66 years). The mean BMI was 30.1 kg/m2 (range, 23.4–34.9 kg/m2). All the patients had a diagnosis of T2DM that had persisted for at least 3 years and evidence of stable treatment with oral hypoglycemic agents or insulin for at least 12 months. The mean duration of T2DM was 9.3 years (range, 3–22 years).
The mean operative time was 185 min, and the median hospital stay was 4.3 days. Four major complications occurred in the short term (30-days), and the mortality rate was 2.6%. The mean postoperative follow-up period was 7 months (range, 4–16 months), and the mean percentage of weight loss was 22%. The mean postoperative BMI was 24.9 kg/m2 (range, 18.9–31.7 kg/m2). An adequate glycemic control was achieved for 86.9% of the patients, and 13.1% had important improvement. The patients whose glycemia was not normalized were using a single oral hypoglycemic agent. No patient needed insulin therapy postoperatively. All the patients except experienced normalization of their cholesterol levels. Targeted triglycerides levels were achieved by 71% of the patients, and hypertension was controlled for 95.8%.
The laparoscopic ileal interposition via either a sleeve gastrectomy or diverted sleeve gastrectomy seems to be a promising procedure for the control of T2DM and the metabolic syndrome. A longer follow-up period is needed.
KeywordsArterial hypertension Dyslipidemia Ileal interposition Neuroendocrine brake Sleeve gastrectomy Type 2 diabetes mellitus
- 1.American Diabetes Association (2004) Prevention or delay of type 2 diabetes. Diabetes Care 27(Suppl 1):S47–S53Google Scholar
- 6.Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S Hansen T, Pedersen O, Holst JJ (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide regardless of etiology and phenotype. J Clin Endocrinol Metab 88:4897–4903PubMedCrossRefGoogle Scholar
- 10.Watts NB, Spanheimer RG, DiGirolamo M, Gebhart SS, Musey VC, Siddiq YK, Phillips LS (1990) Prediction of glucose response to weight loss in patients with non–insulin-dependent diabetes mellitus. Arch Intern Med 151:198–201Google Scholar
- 11.United Kingdom Prospective Diabetes Study 13 (1995) Relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non–insulin-dependent diabetes followed for three years. BMJ 310:83–88Google Scholar
- 25.De Paula AL, Macedo ALV, Prudente A, Silva L, Schraibman V, Neto JG, Pinus J, Cury EK, Szajnbok P, Dario RPD, Bertocco L, Diniz K, Gaudêncio J, Gebin L, D’Orto U, Císon D, Penhavel F (2005). Neuroendocrine brake for the treatment of morbid obesity: preliminary report. Einstein 3:110–114Google Scholar
- 26.American Diabetes Association (2006) Standards of medical care in diabetes: position statement. Diabetes Care 29(Suppl.1):S4–S42Google Scholar
- 33.Rubino F, Forgione A, Cummings DE, Vix M., Gnuli D, Mingrone G, Castagnet M, Marescaux J (2006) The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244:741–749PubMedCrossRefGoogle Scholar
- 34.Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O’Harte FPM, Flatt PR (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3) GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436–2446PubMedCrossRefGoogle Scholar
- 40.Zhou H, Yamada Y, Tsukiyama K, Miyawaki K, Hosokawa M, Nagashima K, Toyoda K, Naitoh R, Mizunoya W, Fushiki T, Kadowaki T, Seino Y (2005) Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 335:937–942PubMedCrossRefGoogle Scholar
- 41.UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38. BMJ 317:703–713Google Scholar
- 44.Lindholm LD, Ibsen H, Dahlof B, Devereux RB, Beever G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Kederballe-Pedersen O, Niemine MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapin S (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for end point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:1004–1010PubMedCrossRefGoogle Scholar